Evidence map›Paper›PMID 33622891›Full record

ArticleIn vivo (Athens, Greece)

Cytotoxic T-lymphocyte Antigen-4 (

Song VAN Nguyen, Levar Shamoun, Kalle Landerholm, Roland E Andersson, Dick Wagsater, Jan Dimberg

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Song VAN NguyenDepartment of Medical Laboratory, Danang University of Medical Technology and Pharmacy, Danang, Vietnam.
Levar ShamounDepartment of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping, Sweden.
Kalle LanderholmDepartment of Surgery, Region Jönköping County, Jönköping, Sweden; Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.
Roland E AnderssonDepartment of Surgery, Region Jönköping County, Jönköping, Sweden; Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.
Dick WagsaterDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Jan DimbergDepartment of Natural Science and Biomedicine, School of Health and Welfare, Jönköping University, Jönköping, Sweden jan.dimberg@ju.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCytotoxic T-lymphocyte antigen-4 (CTLA-4), transiently expressed on T cells, plays a pivotal role in the negative feedback regulation of T-cell activation and proliferation. The aim of the present study was to examine the influence of CTLA-4 gene polymorphism rs3087243 on CRC susceptibility and long-term survival in Swedish patients with CRC. PATIENTS AND

methodsGenotypes of 491 patients and 433 healthy controls were determined, using TaqMan single nucleotide polymorphism (SNP) assays based on polymerase chain reaction.

resultsPatients carrying allele A were found to be at a higher risk of CRC and this allele was found to be more common in patients with disseminated disease compared to localized disease in the right colon. Kaplan-Meier analysis of cancer-specific survival showed that carriers of allele A had the highest risk of CRC-related death.

conclusionThe SNP rs3087243 of the CTLA-4 gene was associated with CRC risk and, therefore, it could be a prognostic marker for Swedish patients with CRC.

Indexed as

Colorectal NeoplasmsCTLA-4 AntigenGenetic Predisposition to DiseaseGene FrequencyGenotypeHumansPolymorphism, Single NucleotideSwedenCTLA-4 AntigenCTLA4 protein, humancolorectal cancerCTLA-4SNP

Identifiers

PMID33622891
PMCPMC8045117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.